AR113014A1 - IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) - Google Patents
IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)Info
- Publication number
- AR113014A1 AR113014A1 ARP180102578A ARP180102578A AR113014A1 AR 113014 A1 AR113014 A1 AR 113014A1 AR P180102578 A ARP180102578 A AR P180102578A AR P180102578 A ARP180102578 A AR P180102578A AR 113014 A1 AR113014 A1 AR 113014A1
- Authority
- AR
- Argentina
- Prior art keywords
- apoc3
- irna agents
- iii
- expression
- compositions
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se refiere a agentes de iARN, por ejemplo, agentes de iARN de cadena doble, capaces de inhibir la expresión del gen de la Apolipoproteína C-III (también denominada APOC3, apoC-III, APOC-III, y APO C-III), y composiciones que incluyen agentes de iARN de APOC3. Los agentes de iARN de APOC3 descritos en la presente pueden estar conjugados con ligandos diana, que incluyen ligandos que incluyen N-acetil-galactosamina, para facilitar la administración a células, que incluyen a hepatocitos. También se describen las composiciones farmacéuticas que incluyen uno o más agentes de iARN de APOC3, opcionalmente con uno o más productos terapéuticos adicionales. La administración de los agentes de iARN de APOC3 in vivo proporciona la inhibición de la expresión del gen APOC3, y puede dar como resultado niveles de triglicéridos y/o niveles de colesterol reducidos en el sujeto. Los agentes de iARN de APOC3 se pueden usar en métodos de tratamiento de enfermedades y trastornos relacionados con APOC3 que incluyen hipertrigliceridemia, enfermedad cardiovascular, y otros trastornos y enfermedades metabólicos relacionados.The present description refers to iRNA agents, for example, double-stranded iRNA agents, capable of inhibiting the expression of the Apolipoprotein C-III gene (also called APOC3, apoC-III, APOC-III, and APO C- III), and compositions including APOC3 iRNA agents. The APOC3 iRNA agents described herein may be conjugated to target ligands, including ligands including N-acetyl-galactosamine, to facilitate delivery to cells, including hepatocytes. Pharmaceutical compositions that include one or more APOC3 iRNA agents, optionally with one or more additional therapeutics, are also described. Administration of APOC3 iRNA agents in vivo provides for inhibition of APOC3 gene expression, and can result in reduced triglyceride levels and / or cholesterol levels in the subject. APOC3 iRNA agents can be used in methods of treating APOC3-related diseases and disorders including hypertriglyceridemia, cardiovascular disease, and other related metabolic disorders and diseases.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556818P | 2017-09-11 | 2017-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113014A1 true AR113014A1 (en) | 2020-01-15 |
Family
ID=69232901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102578A AR113014A1 (en) | 2017-09-11 | 2018-09-11 | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR113014A1 (en) |
-
2018
- 2018-09-11 AR ARP180102578A patent/AR113014A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20017905A (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
| CO2020001740A2 (en) | Iarn agents and compositions to inhibit the expression of angiopoietin type 3 (angptl3) and methods of use | |
| CL2018000803A1 (en) | Compositions and methods to inhibit lpa gene expression. | |
| CL2016003041A1 (en) | Isolated double stranded ribonucleic acids, pharmaceutical compositions comprising them and method for inhibiting the expression of the alas1 gene based on the administration of said composition. divisional application 2725-2014. | |
| UY37565A (en) | IARN ALFA-1 ANTITRIPSIN AGENTS (AAT), COMPOSITIONS INCLUDING IARN AAT AGENTS AND METHODS OF USE | |
| MX2017011422A (en) | Compositions and methods for inhibiting gene expression of factor xii. | |
| ECSP21027262A (en) | RNAi Agents to Inhibit the Expression of 17beta-HSD Type 13 (HSD17B13), Compositions of Such Agents, and Methods of Use | |
| EA201692318A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE ALPHA-1-ANTITRIPSINE GENE | |
| CU20140151A7 (en) | PHARMACEUTICAL COMPOSITION USEFUL IN THE PREVENTION OF A GREATER CARDIOVASCULAR EVENT | |
| ECSP17028310A (en) | Compositions and methods to inhibit the expression of the HAO1 gene (hydroxy acid oxidase 1 (glycolate oxidase)) | |
| UY36671A (en) | RNAi COMPOSITIONS AGAINST Factor XII (Hageman FACTOR) (F12), CALICREINE B, PLASMATIC (FLETCHER FACTOR) 1 (KLKB1), AND FIFTH KINOGEN 1 (KNG1) AND METHODS OF USE | |
| EA201792103A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES | |
| CO2018002198A2 (en) | Pharmaceutical compositions comprising an oligomeric compound to modulate the expression of apolipoprotein (a) | |
| CL2021001488A1 (en) | Mutated piggybac transposase | |
| AR113014A1 (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
| AR113254A1 (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE | |
| EA202090687A1 (en) | RNAi AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
| AR106227A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) | |
| AR114739A1 (en) | RNAi AGENTS TO INHIBIT THE EXPRESSION OF 17b-HSD TYPE 13 (HSD17B13), COMPOSITIONS OF SUCH AGENTS, AND METHODS OF USE | |
| AR113454A1 (en) | IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 | |
| EA202090717A1 (en) | RNAi MEANS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF ANGIOPOETIN-LIKE PROTEIN 3 (ANGPTL3) AND METHODS OF APPLICATION | |
| AR110742A1 (en) | IRNA A-1 ANTITRIPSIN AGENTS (AAT), COMPOSITIONS INCLUDING iRNA AAT AGENTS AND METHODS OF USE | |
| AR109293A1 (en) | IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS | |
| CR20140350A (en) | ENRICHED COMPOSITIONS WITH OMEGA 3 POLYINSATURED FATTY ACIDS DPA IN A FREE ACID FORM | |
| AR096390A1 (en) | COMPOSITIONS OF ARNi DE SERPINA1 AND ITS METHODS OF USE |